Trial · NCT00175019
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment. | Last Visit on treatment (up to 40 months). | Results were summarized by the initial treatment the subject was assigned to before any changes in drug and/or dose. All subjects with a post-baseline serum urate level measurement while receiving their initial treatment were included in the analysis. | percent change from baseline | MEAN |
| SECONDARY | Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline. | Month 12 | Results were summarized by final stable treatment which was the treatment a subject was receiving after drug and/or dose changes were no longer allowed. Subjects with a primary tophus at baseline which was also measured at the Month 12 visit were included in the analysis. | percent change from baseline | MEDIAN |
| PRIMARY | Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1. | Month 1 | Results were summarized by the initial treatment the subject was assigned to before any changes in drug and/or dose. Subjects with a serum urate value at the Month 1 visit and who had not changed from their initial treatment were included in the analysis. | percentage of subjects | NUMBER |
| PRIMARY | Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12. | Month 12 | Results were summarized by the initial treatment the subject was assigned to before any changes in drug and/or dose. Subjects with a serum urate value at the Month 12 visit and who had not changed from their initial treatment were included in the analysis. | percentage of subjects | NUMBER |
| PRIMARY | Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24. | Month 24 | Results were summarized by the initial treatment the subject was assigned to before any changes in drug and/or dose. Subjects with a serum urate value at the Month 24 visit and who had not changed from their initial treatment were included in the analysis. | percentage of subjects | NUMBER |
| PRIMARY | Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36. | Month 36 | Results were summarized by the initial treatment the subject was assigned to before any changes in drug and/or dose. Subjects with a serum urate value at the Month 36 visit and who had not changed from their initial treatment were included in the analysis. | percentage of subjects | NUMBER |
| PRIMARY | Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment. | Last Visit on treatment (up to 40 months). | Results were summarized by the initial treatment the subject was assigned to before any changes in drug and/or dose. All subjects with a post-baseline serum urate level measurement while receiving their initial treatment were included in the analysis. | percentage of subjects | NUMBER |
| SECONDARY | Percent Change From Baseline in Primary Tophus Size at Month 24 for Subjects With Palpable Tophi Measured at Baseline. | Month 24 | Results were summarized by final stable treatment which was the treatment a subject was receiving after drug and/or dose changes were no longer allowed. Subjects with a primary tophus at baseline which was also measured at the Month 24 visit were included in the analysis. | percent change from baseline | MEDIAN |
| SECONDARY | Percent Change From Baseline in Primary Tophus Size at Month 36 for Subjects With Palpable Tophi Measured at Baseline. | Month 36 | Results were summarized by final stable treatment which was the treatment a subject was receiving after drug and/or dose changes were no longer allowed. Subjects with a primary tophus at baseline which was also measured at the Month 36 visit were included in the analysis. | percent change from baseline | MEDIAN |
| SECONDARY | Percent Change From Baseline in Primary Tophus Size at Final Visit for Subjects With Palpable Tophi Measured at Baseline. | Final Visit (up to 40 months). | Results were summarized by final stable treatment which was the treatment a subject was receiving after drug and/or dose changes were no longer allowed. Subjects with a primary tophus at baseline which was also measured while receiving their final stable treatment were included in the analysis. | percent change from baseline | MEDIAN |
| SECONDARY | Percent Change From Baseline in the Total Number of Tophi for Subjects With Palpable Tophi at Final Visit. | Final Visit (up to 40 months). | Results were summarized by final stable treatment which was the treatment a subject was receiving after drug and/or dose changes were no longer allowed. Subjects with a primary tophus at baseline who also had their tophi counted while receiving their final stable treatment were included in the analysis. | percent change from baseline | MEAN |
| SECONDARY | Percentage of Subjects Requiring Treatment for Gout Flare up to Month 12. | Month 12 | Results were summarized by final stable treatment which was the treatment a subject was receiving after drug and/or dose changes were no longer allowed. A subject who reported more than one gout flare during the time interval was counted only once. | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects Requiring Treatment for Gout Flare After Month 12. | After Month 12 to Final Visit | Results were summarized by final stable treatment which was the treatment a subject was receiving after drug and/or dose changes were no longer allowed. A subject who reported more than one gout flare during the time interval was counted only once. | percentage of subjects | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00175019/outcomes